Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026.
Legacy sequencing technologies have, undoubtedly, made comprehensive transcriptome analysis possible and are invaluable for the study of human genetics and mechanisms of diseases. However, legacy ...
We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...
New Trailmaker functionality integrates immune repertoire and whole transcriptome data to deliver rapid, publication-ready insights Parse Biosciences, the leading provider of accessible and scalable ...
ArgenTag joins PacBio to enable instrument-free single-cell kits to support long-read isoform sequencing at single-cell ...
Peking University, August 18, 2025: A research team led by Professor Wang Yangming from the Institute of Molecular Medicine, College of Future Technology, and the Beijing Advanced Center of RNA ...
Immunotherapy has been a revolutionary breakthrough for cancer therapeutics, but it is still hampered in that it only benefits certain patients. Moreover, the molecular determinants of immunotherapy ...
Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results